Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016
Published Jul 20, 2016
141 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding t

  
Source:
Document ID
GMDHC8301IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview101
Therapeutics Development112
  Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) Overview111
  Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) Comparative Analysis121
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies132
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes151
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Products Glance164
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
  Unknown Stage Products191
Acute Renal Failure (ARF) (Acute Kidney Injury) Products under Development by Companies202
Acute Renal Failure (ARF) (Acute Kidney Injury) Products under Investigation by Universities/Institutes221
Acute Renal Failure (ARF) (Acute Kidney Injury) Companies Involved in Therapeutics Development2326
  A1M Pharma AB231
  Adrenomed AG241
  Am-Pharma B.V.251
  Angion Biomedica Corp.261
  Atox Bio Ltd.271
  Cellmid Limited281
  Complexa, Inc.291
  DiaMedica Inc.301
  Digna Biotech, S.L.311
  DURECT Corporation321
  F. Hoffmann-La Roche Ltd.331
  G1 Therapeutics, Inc.341
  Kringle Pharma, Inc.351
  NephroGenex, Inc.361
  NeuroVive Pharmaceutical AB371
  Noorik Biopharmaceuticals AG381
  Noxxon Pharma AG391
  Orion Oyj401
  ProMetic Life Sciences Inc.411
  Quark Pharmaceuticals, Inc.421
  SBI Pharmaceuticals Co., Ltd.431
  Spherium Biomed S.L.441
  STATegics, Inc.451
  Stealth BioTherapeutics Inc.461
  Thrasos Therapeutics Inc.471
  Torrent Pharmaceuticals Limited481
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Assessment4910
  Assessment by Monotherapy Products491
  Assessment by Combination Products501
  Assessment by Target512
  Assessment by Mechanism of Action532
  Assessment by Route of Administration552
  Assessment by Molecule Type572
Drug Profiles5969
  (aminolevulinic acid hydrochloride + sodium ferrous citrate) Drug Profile591
  A1M-001 Drug Profile601
  AB-103 Drug Profile613
  adrecizumab Drug Profile641
  BB-3 Drug Profile654
  CAB-101 Drug Profile691
  Cardiotrophin-1 Drug Profile702
  CXA-10 Drug Profile722
  cyclosporine Drug Profile745
  DM-199 Drug Profile794
  DUR-928 Drug Profile832
  elamipretide Drug Profile857
  HYPER-IL-6 Drug Profile921
  KP-100IT Drug Profile932
  levosimendan Drug Profile954
  MG-53 Drug Profile992
  MIX-9 Drug Profile1011
  N-003 Drug Profile1021
  NOXD-21 Drug Profile1031
  PBI-4419 Drug Profile1041
  Pyridoxamine Dihydrochloride Drug Profile1054
  QPI-1002 Drug Profile1093
  R-190 Drug Profile1122
  Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia Drug Profile1143
  Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis Drug Profile1171
  RLS-003 Drug Profile1181
  RO-6839328 Drug Profile1191
  Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer Drug Profile1201
  Small Molecule to Inhibit HDAC for Acute Kidney Injury Drug Profile1211
  SP-15016 Drug Profile1221
  STSE-15 Drug Profile1232
  THR-184 Drug Profile1252
  TRC-160334 Drug Profile1271
Acute Renal Failure (ARF) (Acute Kidney Injury) Dormant Projects1281
Acute Renal Failure (ARF) (Acute Kidney Injury) Discontinued Products1291
Acute Renal Failure (ARF) (Acute Kidney Injury) Product Development Milestones13010
  Featured News &Press Releases1301
    Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment1301
    May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial1311
    Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury1311
    Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation1321
    Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-10021321
    Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)1331
    Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-9281331
    Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury1341
    Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study1351
    Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision1351
    Nov 04, 2015: DiaMedica Provides Corporate Update1361
    Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin1371
    Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego1371
    Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials1381
    Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury1382
Appendix1402
  Methodology1401
  Coverage1401
  Secondary Research1401
  Primary Research1401
  Expert Panel Validation1401
  Contact Us1401
  Disclaimer1411

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Renal-Failure-ARF-Acute-Kidney-Injury-Pipeline-Review-H2-2016-2088-16264>
  
APA:
Global Markets Direct - Market Research. (2016). Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Renal-Failure-ARF-Acute-Kidney-Injury-Pipeline-Review-H2-2016-2088-16264>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.